^(90)钇玻璃微球内放射治疗原发性肝癌的临床研究

Interventional treatment of primary liver cancer with intrahepatic^(90) Y glass microspheres

目的 :探讨90 钇玻璃微球内放射治疗原发性肝癌的疗效及其与肿瘤血供的关系。方法 :搜集 2 0 0 1年 3～ 12月采用含90 钇玻璃微球的“夹心面包”法治疗的原发性肝癌 18例 ,根据肝动脉造影情况将其肿瘤血供分为 3类 ,探讨肿瘤血供与疗效的关系。结果 :术后 13例肿瘤缩小 ,6例缩小明显 ,其中Ⅰ类 4例 ;12例患者术后AFP不同程度下降 ,平均生存期为 8.8个月。 3类患者疗效间的比较采用Ridit检验 ,结果Ⅰ类疗效最好 ,与Ⅱ类 (P <0 .0 5 )及Ⅲ类 (P <0 .0 1)间的差异有显著意义。结论 :应用90 钇玻璃微球治疗原发性肝癌尤其是对富血供的局限性或单发性肝癌是一种安全、有效、有潜力的治疗方法。

Objective:To evaluate the relationship between clinical effects of hepatic radioembolization with Yttrium 90 ( 90 Y) glass microspheres and the tumor vascularity in the treatment of primary liver cancer.Methods:Hepatic radio- embolization was performed using ”sandwich form” in 18 patients with primary liver cancer during the period from March to Dec of 2001.PHC was classified into three types according to the arteriographic hepatic findings.Results:On CT scan, significant reduction of tumor size was seen in 13 cases,six of them is more obvious;alpha fetoprotein level had been reduced after treatment in 12 patients.Survial time of all patient was 8.8 months in average.The comparison of treatment in three types of PHC was carried out by Ridit test. The result in type Ⅰ was better than type Ⅱ (P<0.05) and type Ⅲ (P< 0.01). Conclusion:Hepatic radioembolization with Yttrium 90 glass microspheres is safe,effective and potential for the treatment of primary liver cancer,especially for the localized and hypervascular lesion.